A total of 33 680 nuclear power plants (NPPs) workers were monitored and recorded from 1990 to 2007. According to the record, the average individual radiation dose has been decreasing continually from 3.20 mSv man(-1) in 1990 to 1.12 mSv man(-1) at the end of 2007. After the International Commission on Radiological Protection 60 recommendation was generalised in South Korea, no NPP workers received >20 mSv radiation, and the numbers of relatively highly exposed workers have been decreasing continuously. The age distribution of radiation workers in NPPs was composed mainly of 20-30 y olds (83 %) for 1990-1994 and 30-40 y olds (75 %) for 2003-2007. The difference in individual average dose by age was not significant. Most (77 %) of the NPP radiation exposures from 1990 to 2007 occurred mostly during the refueling period. With regard to exposure type, the majority of exposures was external exposures, representing 95 % of the total exposures, whereas internal exposures represented only 5 %. External effective dose was affected mainly by gamma radiation exposure, with an insignificant amount of neutron exposure. As for internal effective dose, tritium in the pressurised heavy water reactor was the biggest cause of exposure.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/rpd/ncq091 | DOI Listing |
J Bone Oncol
February 2025
Unit of Oral Medicine and Dentistry for Frail Patients, Department of Rehabilitation, Fragility, and Continuity of Care, Regional Center for Research and Care of MRONJ, University Hospital Palermo, Palermo, PA, Italy.
Background: Low-doses of bone modifying agents (LD-BMAs) compared to those used to treat bone metastases are used in breast or prostate cancer patients on adjuvant endocrine therapy to prevent Cancer Treatment Induced Bone Loss (CTIBL). Their use is associated with an increased risk of developing Medication-Related Osteonecrosis of the Jaw (MRONJ). However, there is not clarity about strategies aimed to minimize the MRONJ risk in cancer patients at different conditions as low- vs high-doses of BMA.
View Article and Find Full Text PDFJ Soc Cardiovasc Angiogr Interv
December 2024
Department of Pediatric Cardiology, Wilhelmina Children's Hospital, University Medical Center of Utrecht, Utrecht, the Netherlands.
Background: Three-dimensional rotational angiography (3DRA) is a promising advancement to guide cardiac catheterizations. It is used with restraint in critically ill infants with congenital heart disease (CHD) due to the lack of research conducted within this patient group.
Methods: Data of all infants with CHD and a body weight <5 kg who underwent cardiac catheterization with the use of 3DRA between November 2011 and April 2021 were retrospectively analyzed.
J Soc Cardiovasc Angiogr Interv
December 2024
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Background: Advancements in cardiac catheterization have improved survival for pediatric congenital heart disease patients, but the associated ionizing radiation risks necessitate ethical consideration.
Methods: This study presents an empirical model, developed from 3131 unique pediatric procedures, to establish alert levels based on a patient's lateral thickness of the thorax for various procedural categories during diagnostic or interventional cardiac catheterization. The model uses linear regression of logarithmic reference air kinetic energy released per unit mass (KERMA) and air KERMA area product, also referred to as dose area product, to set alert levels at the top 95% and 99% of patient data.
Oncol Lett
March 2025
State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, P.R. China.
High-intensity focused ultrasound thermal ablation (HIFU) is a novel non-invasive technique in the treatment of liver metastases (LIM) that allows focal destruction and is not affected by dose limits. This retrospective study aimed to explore the efficacy of HIFU in improving survival and the safety of the method in newly diagnosed patients with cancer with LIM who received first-line immune checkpoint inhibitor (ICI) therapy. Between January 2018 and December 2023, data from 438 newly diagnosed patients with cancer and LIM who were treated at Mianyang Central Hospital (Mianyang, China) were reviewed.
View Article and Find Full Text PDFCancer Rep (Hoboken)
January 2025
Department of Pharmacology, Clinical Pharmacy and Pharmacy Practices, Faculty of Health Sciences, University of Nairobi, Nairobi, Kenya.
Background: In developing countries, the treatment outcomes of Burkitt lymphoma are poor due to the poorly equipped healthcare systems. In addition, there is limited comprehensive data within the African continent, including Kenya, about the outcomes of treatment for this cancer.
Aims: To assess treatment outcomes and variables associated with an increased risk of death from disease progression or treatment-related toxicities among Burkitt lymphoma pediatric patients at the Kenyatta National Hospital (KNH).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!